Better Buy: Moderna vs. Gilead Sciences
Moderna (NASDAQ: MRNA) and Gilead Sciences (NASDAQ: GILD) may have gotten your attention in recent weeks if you've been following coronavirus stocks. Moderna was the first to enter human trials with its investigational vaccine. Gilead's big moment came when the U.S. Food and Drug Administration granted its investigational treatment, remdesivir, emergency use authorization. So, we can say both companies are leaders in the coronavirus space.
But there's more to these biotech players than their coronavirus programs. Both have full pipelines, and Gilead has a portfolio of commercialized products as well. Which is a better buy today? Let's take a closer look.
Image Source: Getty Images
Source Fool.com
